Literature DB >> 19299433

Activation of prostaglandin E2 EP1 receptor increases arteriolar tone and blood pressure in mice with type 2 diabetes.

Ibolya Rutkai1, Attila Feher, Nora Erdei, Daniel Henrion, Zoltan Papp, Istvan Edes, Akos Koller, Gabor Kaley, Zsolt Bagi.   

Abstract

AIMS: Type 2 diabetes mellitus is frequently associated with hypertension, but the underlying mechanisms are not completely understood. We tested the hypothesis that activation of type 1 prostaglandin E(2) (PGE(2)) receptor (EP1) increases skeletal muscle arteriolar tone and blood pressure in mice with type 2 diabetes. METHODS AND
RESULTS: In 12-week-old, male db/db mice (with homozygote mutation in leptin receptor), systolic blood pressure was significantly elevated, compared with control heterozygotes. Isolated, pressurized gracilis muscle arterioles ( approximately 90 microm) of db/db mice exhibited an enhanced pressure- and angiotensin II (0.1-10 nM)-induced tone, which was reduced by the selective EP1 receptor antagonist, AH6809 (10 microM), to the level observed in arterioles of control mice. Exogenous application of PGE(2) (10 pM-100 nM) or the selective agonist of the EP1 receptor, 17-phenyl-trinor-PGE(2) (10 pM-100 nM), elicited arteriolar constrictions that were significantly enhanced in db/db mice (max: 31 +/- 4 and 29 +/- 5%), compared with controls (max: 20 +/- 2 and 14 +/- 3%, respectively). In the aorta of db/db mice, an increased protein expression of EP1, but not EP4, receptor was also detected by western immunoblotting. Moreover, we found that oral administration of the EP1 receptor antagonist, AH6809 (10 mg/kg/day, for 4 days), significantly reduced the systolic blood pressure in db/db, but not in control mice.
CONCLUSION: Activation of EP1 receptors increases arteriolar tone, which could contribute to the development of hypertension in the db/db mice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19299433      PMCID: PMC2695704          DOI: 10.1093/cvr/cvp098

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  39 in total

Review 1.  Prostanoid receptors: subtypes and signaling.

Authors:  R M Breyer; C K Bagdassarian; S A Myers; M D Breyer
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

2.  Role of periaqueductal grey prostaglandin receptors in formalin-induced hyperalgesia.

Authors:  Patrizia Oliva; Liberato Berrino; Vito de Novellis; Enza Palazzo; Ida Marabese; Dario Siniscalco; Mariantonietta Scafuro; Loredana Mariani; Francesco Rossi; Sabatino Maione
Journal:  Eur J Pharmacol       Date:  2005-12-19       Impact factor: 4.432

Review 3.  Diabetes, hypertension, and cardiovascular disease: an update.

Authors:  J R Sowers; M Epstein; E D Frohlich
Journal:  Hypertension       Date:  2001-04       Impact factor: 10.190

4.  The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure.

Authors:  J L Stock; K Shinjo; J Burkhardt; M Roach; K Taniguchi; T Ishikawa; H S Kim; P J Flannery; T M Coffman; J D McNeish; L P Audoly
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

5.  Enhanced role for RhoA-associated kinase in adrenergic-mediated vasoconstriction in gracilis arteries from obese Zucker rats.

Authors:  Jay S Naik; Lusha Xiang; Robert L Hester
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-09-01       Impact factor: 3.619

6.  Influence of type II diabetes on arterial tone and endothelial function in murine mesenteric resistance arteries.

Authors:  G J Lagaud; E Masih-Khan; S Kai; C van Breemen; G P Dubé
Journal:  J Vasc Res       Date:  2001 Nov-Dec       Impact factor: 1.934

Review 7.  Diabetes mellitus and diabetes-associated vascular disease.

Authors:  D Kirpichnikov; J R Sowers
Journal:  Trends Endocrinol Metab       Date:  2001-07       Impact factor: 12.015

8.  Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors.

Authors:  William B White; Jeffrey Kent; Addison Taylor; Kenneth M Verburg; James B Lefkowith; Andrew Whelton
Journal:  Hypertension       Date:  2002-04       Impact factor: 10.190

9.  Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting.

Authors:  Youfei Guan; Yahua Zhang; Jing Wu; Zhonghua Qi; Guangrui Yang; Dou Dou; Yuansheng Gao; Lihong Chen; Xiaoyan Zhang; Linda S Davis; Mingfeng Wei; Xuefeng Fan; Monica Carmosino; Chuanming Hao; John D Imig; Richard M Breyer; Matthew D Breyer
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 10.  The endothelium and vascular inflammation in diabetes.

Authors:  Martin M Hartge; Thomas Unger; Ulrich Kintscher
Journal:  Diab Vasc Dis Res       Date:  2007-06       Impact factor: 3.291

View more
  19 in total

1.  Impaired blood pressure recovery to hemorrhage in obese Zucker rats with orthopedic trauma.

Authors:  Lusha Xiang; Silu Lu; William Fuller; Arun Aneja; George V Russell; Louis B Jones; Robert Hester
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-10-14       Impact factor: 4.733

2.  Angiotensin II-dependent hypertension requires cyclooxygenase 1-derived prostaglandin E2 and EP1 receptor signaling in the subfornical organ of the brain.

Authors:  Xian Cao; Jeffrey R Peterson; Gang Wang; Josef Anrather; Colin N Young; Mallikarjuna R Guruju; Melissa A Burmeister; Costantino Iadecola; Robin L Davisson
Journal:  Hypertension       Date:  2012-02-27       Impact factor: 10.190

3.  Berberine regulates the expression of E-prostanoid receptors in diabetic rats with nephropathy.

Authors:  Li Qin Tang; Sheng Liu; Shan Tang Zhang; Ling Na Zhu; Feng Ling Wang
Journal:  Mol Biol Rep       Date:  2014-02-01       Impact factor: 2.316

4.  CD36 protein is involved in store-operated calcium flux, phospholipase A2 activation, and production of prostaglandin E2.

Authors:  Ondrej Kuda; Christopher M Jenkins; James R Skinner; Sung Ho Moon; Xiong Su; Richard W Gross; Nada A Abumrad
Journal:  J Biol Chem       Date:  2011-03-31       Impact factor: 5.157

5.  H2O2 stimulates cystic fibrosis transmembrane conductance regulator through an autocrine prostaglandin pathway, using multidrug-resistant protein-4.

Authors:  Gregory E Conner; Pedro Ivonnet; Murline Gelin; Philip Whitney; Matthias Salathe
Journal:  Am J Respir Cell Mol Biol       Date:  2013-10       Impact factor: 6.914

6.  Cyclooxygenase 1-derived prostaglandin E2 and EP1 receptors are required for the cerebrovascular dysfunction induced by angiotensin II.

Authors:  Carmen Capone; Giuseppe Faraco; Josef Anrather; Ping Zhou; Costantino Iadecola
Journal:  Hypertension       Date:  2010-03-01       Impact factor: 10.190

Review 7.  Distinct roles of central and peripheral prostaglandin E2 and EP subtypes in blood pressure regulation.

Authors:  Tianxin Yang; Yaomin Du
Journal:  Am J Hypertens       Date:  2012-06-14       Impact factor: 2.689

8.  The EP1/EP3 receptor agonist 17-pt-PGE2 acts as an EP4 receptor agonist on endothelial barrier function and in a model of LPS-induced pulmonary inflammation.

Authors:  Anna Theiler; Viktoria Konya; Lisa Pasterk; Jovana Maric; Thomas Bärnthaler; Ilse Lanz; Wolfgang Platzer; Rufina Schuligoi; Akos Heinemann
Journal:  Vascul Pharmacol       Date:  2016-09-21       Impact factor: 5.773

9.  Development of an in vivo active, dual EP1 and EP3 selective antagonist based on a novel acyl sulfonamide bioisostere.

Authors:  Jason D Downey; Sam A Saleh; Thomas M Bridges; Ryan D Morrison; J Scott Daniels; Craig W Lindsley; Richard M Breyer
Journal:  Bioorg Med Chem Lett       Date:  2012-11-24       Impact factor: 2.823

10.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.